Search clinical trials for: IO-108 pembrolizumab

Total 6866 results

City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Metastatic Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Androgen Receptor Positive

United States
OHSU Knight Cancer Institute
Merck Sharp & Dohme LLC; Oregon Health and Science University; Collins Medical...

Active, not recruiting

Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide

Castration-Resistant Prostate Carcinoma | Recurrent Prostate Carcinoma | PSA Progression | Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma Cancer AJCC v8

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Minimal Residual Disease | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
University Hospital, Brest
Groupe Français de Pneumo-Cancérologie

Recruiting

PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % (PERSEE)

Non-small-cell Lung Cancer

France
Binhui Biopharmaceutical Co., Ltd.

Recruiting

OH2 Injection in Solid Tumors

Melanoma | Solid Tumor

China
University of Virginia
Merck Sharp & Dohme LLC

Recruiting

Her2-BATS and Pembrolizumab in Metastatic Breast Cancer (Breast-47)

Metastatic Breast Cancer

United States
Samsung Medical Center

Completed

Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
BerGenBio ASA
Merck Sharp & Dohme LLC

Terminated

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

Triple Negative Breast Cancer | Inflammatory Breast Cancer Stage IV

Spain, United States, United Kingdom, Norway
University of Texas Southwestern Medical Center

Withdrawn

Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome

Cutaneous T-Cell Lymphomas

United States
Abramson Cancer Center of the University of Pennsylvania

Withdrawn

RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy

Urothelial Cancer

United States
University of Illinois at Chicago

Recruiting

A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC) (LUNG-IST-127)

Metastatic Squamous Non-Small Cell Lung Carcinoma

United States
Oncotelic Inc.

Not yet recruiting

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

Malignant Pleural Mesothelioma

United States
Merck Sharp & Dohme LLC

Recruiting

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)

Colorectal Cancer

United States, Belgium, Canada, Germany, Italy, Korea, Republic of, Poland, Russian Federation, Spain, Turkey, United Kingdom, France, Denmark, Romania, Estonia, Hungary, Guatemala, Costa Rica, Lithuania, Greece, Colombia, Netherl...
Universitair Ziekenhuis Brussel

Recruiting

Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors (Luscid)

Solid Tumor | Non Small Cell Lung Cancer

Belgium
Queen Mary University of London
Merck Sharp & Dohme LLC; European Institute of Oncology

Withdrawn

Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer (PELICAN)

Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Glioblastoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Pancreatic Ductal Adenocarcinoma | Endocervical Cancer

United States, Korea, Republic of, Taiwan
Harbour BioMed (Guangzhou) Co. Ltd.

Not yet recruiting

A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

Solid Tumor
Silverback Therapeutics

Active, not recruiting

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

HER2 Positive Solid Tumors

United States, Korea, Republic of, Australia
Baptist Health South Florida
Merck Sharp & Dohme LLC; Miami Cancer Institute

Completed

Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors

Solid Tumor, Adult

United States
International AIDS Vaccine Initiative
Coalition for Epidemic Preparedness Innovations

Recruiting

A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa

Lassa Fever

Ghana, Liberia, Nigeria
Amgen

Not yet recruiting

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer

Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Yonsei University

Completed

Lower Femtosecond Laser Energy Levels Lead to Better Visual Recovery After Small-incision Lenticule Extraction for Myopia

Myopia

Korea, Republic of
Case Comprehensive Cancer Center

Recruiting

Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (RGBM)

Glioblastoma, Adult

United States
Aravax Pty Ltd

Recruiting

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Immune System Diseases | Peanut Hypersensitivity | Peanut Allergy | Peanut-Induced Anaphylaxis

United States, Australia
MedSIR
Merck Sharp & Dohme LLC

Active, not recruiting

Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (PECATI)

Metastatic Thymic Carcinoma | Thymoma Type B3

Spain, France, Italy
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC

Withdrawn

Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer

Metastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Microsatellite Stable | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA... and other conditions

United States
SMT bio Co., Ltd.

Recruiting

Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer

Biliary Tract Cancer

Korea, Republic of
Sidney Kimmel Comprehensive Cancer Center at Johns...
Merck Sharp & Dohme LLC

Completed

Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

Acute Myeloid Leukemia

United States
PharmAbcine

Active, not recruiting

TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

Australia
Agenus Inc.

Terminated

Study of AGEN1884 With Pembrolizumab in 1L NSCLC

NSCLC Stage IV

New Zealand, Australia
Pfizer
Merck Sharp & Dohme LLC

Completed

A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)

Advanced Solid Tumors

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Recurrent Glioblastoma

Recurrent Glioblastoma | Recurrent Gliosarcoma

United States
Sumitomo Pharma Oncology, Inc.
Syneos Health

Completed

A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

Neoplasms

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

Urothelial Cancer
Merck Sharp & Dohme LLC

Completed

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

Head and Neck Squamous Cell Carcinoma
Merck Sharp & Dohme LLC

Terminated

Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

Advanced Melanoma

United States
National University Hospital, Singapore
Merck Sharp & Dohme LLC; Adagene Inc

Recruiting

Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer (ComPACT)

Triple Negative Breast Cancer | Advanced Solid Tumor

Singapore
University of Erlangen-Nürnberg Medical School

Recruiting

Radiotherapy With Pembrolizumab in Metastatic HNSCC

Head and Neck Squamous Cell Carcinoma

Germany
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Stage IV Lung Cancer AJCC v8 | Unresectable Malignant Solid Neoplasm | Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Malignant Solid Neoplasm | Unresectable Melanoma | Clinical... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Recurrent Pancreatic Adenocarcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer

Metastatic Malignant Neoplasm in the Bone | Triple-Negative Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

Malignant Solid Neoplasm | Head and Neck Squamous Cell Carcinoma

United States
Queensland Institute of Medical Research
Merck Sharp & Dohme LLC; Royal Brisbane and Women's Hospital; Princess Alexandra... and other collaborators

Recruiting

T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma (TCaP)

Glioblastoma Multiforme | Astrocytoma, Grade IV

Australia
TriSalus Life Sciences, Inc.

Active, not recruiting

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Hepatocellular Carcinoma | Intrahepatic Cholangiocarcinoma

United States
Monopteros Therapeutics Inc.

Recruiting

A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Metastatic Cancer | Advanced Solid Tumor | Advanced Cancer | Solid Tumor, Adult | Refractory Cancer

United States
Samsung Medical Center

Recruiting

Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer

Gastric Cancer

Korea, Republic of
PharmAbcine

Active, not recruiting

TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma

Recurrent Glioblastoma

Australia
Wakayama Medical University
Merck Sharp & Dohme LLC

Unknown

Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer

Small Cell Lung Cancer Extensive Stage

Japan
Neurogene Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

Solid Tumor | Advanced Solid Tumor

United States, Australia, Canada

Search clinical trials for: IO-108 pembrolizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations